Taipei, Taiwan, July 26, 2024 — Lotus Pharmaceutical ("Lotus" or "the Company", Taiwan TWSE ticker: 1795), a leading Taiwan-based global pharmaceutical company, has been honored with the "2024 Taiwan BIO Awards - Outstanding Company of the Year" at the BIO Asia-Taiwan conference. This prestigious award recognizes Lotus' exceptional operational performance and strategic development in Taiwan's biotechnology industry, standing out among a highly competitive field of nominees. The award was accepted on behalf of the company by our APAC Chief Commercial Officer, Valerie Lau.
The independent panel of judges praised Lotus for its outstanding achievements in multiple areas, including operational performance and development strategy, which have driven remarkable progress year after year.
"We are thrilled to receive this prestigious award, which is a testament to the hard work and dedication of our employees," said Petar Vazharov, CEO of Lotus. "We will continue to innovate and provide high-quality medical solutions to patients worldwide, upholding the highest standards and contributing to the health sector in Taiwan."
As a global pharmaceutical company, Lotus boasts a diverse product portfolio with a strong presence in over 150 countries worldwide. The company's revenue has consistently grown over the past three years, reaching NT$17 billion in 2023, with a notable annual revenue growth rate of 16%, a net profit margin of 24.2%, and a per capita revenue of NT$12 million. These achievements solidify Lotus' position as a benchmark company in the Taiwan pharmaceutical industry.
The judges also commended Lotus' operational strategy, which leverages Taiwan's manufacturing capabilities and aligns with the country's strengths. The company's "Two-Pronged Expansion Strategy" has enabled it to expand its global presence, introducing both complex generic and innovative drugs to Asia and beyond. In 2023, Lotus completed 29 licensing agreements and 25 business development projects, further solidifying its position as a global diversified pharmaceutical platform. The company's research and development team of over 200 scientists from around the world has also been instrumental in driving innovation and product development.
This award marks a significant milestone for Lotus. The company remains committed to enhancing Taiwan's pharmaceutical research and development, equal access to healthcare, and environmental protection as part of its corporate social responsibility.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate Communication
+886 2 2700 5908
investor@lotuspharm.com